Brief: Nanobiotix SA H1 Net Loss At EUR 26.4 Mln

Nanobiotix SA

29/09/2022 07:24

Sept 29 (Reuters) - Nanobiotix SA  NANOB.PA :
    * REPORTED ON WEDNESDAY EUR 63.0 MILLION IN CASH AND CASH
EQUIVALENTS AS OF JUNE 30, 2022
    * CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2022 EXPECTED TO
FUND
DEVELOPMENT PROGRAMS INTO Q1 2024
    * AS OF JUNE 30, 2022, REVENUE AND OTHER INCOME REMAINED
STABLE VS
APPROXIMATELY SAME FIGURE FOR SIX MONTHS ENDED JUNE 30, 2021
    * AS OF JUNE 30, 2022, NET LOSS ATTRIBUTABLE TO COMMON
SHAREHOLDERS WAS EUR 26.4 MLN (EUR 0.76 PER SHARE) VS EUR 30.4
MLN (EUR 0.88 PER SHARE) IN 2021
    * OUTLOOK: PLAN TO SUBMIT PROTOCOL FOR POTENTIAL
REGISTRATION
PATHWAY FOR NBTXR3 IMMUNOTHERAPY COMBINATION TO US FDA BY Q1 23
    * R&D EXPENSES FOR SIX MONTHS ENDED JUNE 30, 2022, WERE EUR
16.6
MILLION

Source text for Eikon:  urn:newsml:reuters.com:*:nBw5Sgvmha
Further company coverage:  NANOB.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))